1 day ago · Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.

1 day ago · Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy.

2 days ago · The Goldman Sachs Group reduced their price objective on shares of Moderna from $112.00 to $99.00 and set a "buy" rating for the company in a research report on Tuesday.

1 day ago · Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance represents the second in a …

1 day ago · Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need to know.

1 day ago · Goldman Sachs has turned more cautious on Moderna as the biotech struggles against strong competition from other vaccine makers. Analyst Salveen Richter downgraded …

1 day ago · Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Read more here.

1 day ago · Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (WBAG:MRNA) from Buy to Neutral. There are 1,449 funds or institutions reporting …

1 day ago · Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months. Moderna …

1 day ago · Goldman Sachs Downgrades Moderna to Neutral From Buy, Adjusts Price Target to $51 From $99